Current Report Filing (8-k)
October 21 2020 - 8:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 21, 2020
Trevi Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-38886
|
|
45-0834299
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
195 Church Street, 14th Floor
New Haven, Connecticut
|
|
06510
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(203) 304-2499
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, $0.001 par value per share
|
|
TRVI
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
On October 21, 2020, Trevi Therapeutics, Inc. (the Company) announced that patient screening had resumed in its Phase 2 clinical trial of
Haduvio (nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis. The Company also announced that with the randomization of the 180th subject in the
Companys Phase 2b/3 PRISM trial of Haduvio for severe pruritus in patients with prurigo nodularis, the Company had enrolled 50% of the planned subjects in the expanded trial following the July 2020 sample size re-estimation.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
TREVI THERAPEUTICS, INC.
|
|
|
|
|
Date: October 21, 2020
|
|
|
|
By:
|
|
/s/ Jennifer L. Good
|
|
|
|
|
|
|
Name: Jennifer L. Good
|
|
|
|
|
|
|
Title: President and Chief Executive Officer
|
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024